Cleveland Clinic Reports Real-World Outcomes of KEYNOTE-522 Regimen in Triple-Negative Breast Cancer Treatment

Cleveland Clinic researchers have published groundbreaking real-world evidence on the implementation of the KEYNOTE-522 regimen for triple-negative breast cancer treatment, offering crucial insights for oncologists and surgical teams worldwide. The findings, published in the Annals of Surgical Oncology, demonstrate both the treatment's effectiveness and important considerations for surgical planning.

The analysis, encompassing 240 patients treated between 2019 and 2022, validates the clinical trial results while revealing new insights about surgical outcomes and safety considerations. "As one of the first institutes to report our experience with KEYNOTE-522 after the clinical trial, we have a responsibility to share our real-world findings," states Dr. Julie Lang, Professor of Surgery and Director of the Eastern Region of Cleveland Clinic's Breast Cancer Program.

Enhanced Surgical Options and Treatment Outcomes

The KEYNOTE-522 regimen, which combines traditional chemotherapy with immunotherapy before surgical intervention, has demonstrated remarkable effectiveness in treating triple-negative breast cancer, a variant known for its poor prognosis and high recurrence rates. The treatment's success in reducing tumor size has significantly expanded surgical options for patients.

Key findings from the analysis include:

• A notable increase in patients qualifying for breast-conserving therapy
• Reduced necessity for lymphadenectomies
• Improved survival rates consistent with clinical trial data
• Patient preference for mastectomies with reconstruction, despite eligibility for less invasive options

Critical Safety Considerations

The real-world implementation has unveiled important safety considerations not fully addressed in the original clinical trials. Notably, Cleveland Clinic observed higher rates of hormone-related side effects than previously reported. This finding has led to the implementation of comprehensive hormone monitoring protocols.

"At Cleveland Clinic, we continuously monitor hormone levels in our patients receiving immunotherapy treatment," Dr. Lang explains. "It's because we monitor hormones that we can catch potential issues for surgery and keep patients safe – but not all hospital systems keep track of these things the same way."

Treatment Planning Implications

The study's findings carry significant implications for healthcare institutions implementing the KEYNOTE-522 regimen. While the treatment continues to show promising results, the research emphasizes the importance of:

• Regular hormone level monitoring
• Comprehensive pre-surgical assessment
• Individualized surgical planning
• Patient education regarding treatment options

Despite the identified challenges, Dr. Lang maintains strong support for the KEYNOTE-522 regimen, emphasizing that proper monitoring and management of potential side effects are key to optimal outcomes. The findings provide valuable guidance for healthcare institutions as they incorporate this innovative treatment approach into their standard of care.